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Abstract:  Background: New developments in the field of targeted therapies or biologic agents led more effective 
management of ankylosing spondylitis (AS) and rheumatoid arthritis (RA). Recommendations for the management of 
rheumatic diseases propose to reduce inappropriate use of medications, minimize variations among countries, and enable 
cost-effective use of health care resources. 
Objective: The aim this study was to evaluate conceptual agreement of ASsessment in SpondyloArthritis International 
Society (ASAS) and the EUropean League Against Rheumatism (EULAR) recommendations for the management of AS 
and EULAR recommendations for RA and to assess the rate of application among Turkish physiatrists in daily clinical 
practice. 
Methods: An online survey link has been sent to 1756 Turkish physiatrists with e-mails asking to rate agreement on 11-
item ASAS/EULAR AS recommendations and 15-item EULAR RA recommendations with synthetic and biological 
disease-modifying anti-rheumatic drugs. Also barriers and difficulties for using biologic agents were assessed. 
Results: Three hundred nine physiatrists (17.5%) completed the survey. The conceptual agreement with both 
recommendations was very high (Level of agreement; mean 8.35±0.82 and 8.90± 0.67 for RA and AS recommendations, 
respectively), and the self-declared application of overall recommendations in the clinical practice was also high for both 
RA and AS (72.42% and 75.71%, respectively). 
Conclusion: Turkish physiatrists are in good conceptual agreement with the evidence-based recommendations for the 
management of AS and RA. These efforts may serve to disseminate the knowledge and increase the current awareness 
among physicians who serve to these patients and also implementation of these recommendations is expected to increase 
as well. 
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INTRODUCTION 
  New pivotal innovations in the field of targeted therapies 
or namely treatment with biological agents led more 
effective management of spondyloarthropathies (SpA) 
including ankylosing spondylitis (AS) and rheumatoid 2   The Open Rheumatology Journal, 2012, Volume 6  Ozgocmen et al. 
arthritis (RA). With these rapid developments in the field, 
many experts or officially representative groups proposed 
recommendations or guidelines for the management of 
rheumatic diseases. These novel therapies are reasonably 
expensive and potentially have side effects which further 
require standardization in their use. Recommendations for 
the management or treatment of rheumatic diseases, whether 
at international or national level, propose to reduce 
inappropriate use of these medications, minimize variations 
from country to country, and enable cost-effective use of 
health care resources. 
  In 2006 ASsessment in SpondyloArthritis International 
Society (ASAS) and the EUropean League Against 
Rheumatism (EULAR) published recommendations for the 
management of AS which were developed based on evidence 
and expert opinion [1]. Evaluation of these recommendations 
by a large number of rheumatologists from 10 countries 
revealed high degree of conceptual agreement [2]. 
Furthermore ASAS group pointed out the necessity of 
dissemination and evaluation of these recommendations 
among patients with AS. Kiltz et al., first developed patient 
version of these recommendations with an international 
collaboration of English speaking patients [3] and then 
German [4] and Turkish translation [5] of the patient 
versions have been published. Also some of the countries 
have developed their own recommendations or assessed the 
conceptual agreement with these recommendations at 
national level [6-8]. Recently ASAS/EULAR 
recommendations for the management of AS have been 
updated [9]. 
  Therapeutic strategies in RA have undergone dramatic 
changes during the past decade. Novel therapies other than 
synthetic disease modifying anti-rheumatic drugs (DMARDs) 
have been introduced. These biologic agents, which target 
tumor necrosis factor (TNF), the interleukin 1 (IL-1) receptor, 
the IL-6 receptor, B lymphocytes and T-cell costimulation, are 
highly effective. These rapid and tremendous changes in 
targeted therapies as well as strategies for initiation and follow 
up of early disease overwhelmed physicians and patients. In a 
recent survey, which was applied during EULAR Congress, 
inconsistencies in therapeutic targets and treatment strategies 
among rheumatologists have been recognized [10]. These 
discrepancies may strongly be related to the fact that 
reimbursement strategies and patients and physicians 
perspectives change from country to country. In order to “find a 
consensus on recommendations” for the management of RA 
with synthetic and biological DMARDs, EULAR initiated the 
project and recent recommendations have been published [11]. 
  Turkish physiatrists and rheumatologists are actively 
involved in both pharmacological and non-pharmacological 
treatment of AS and RA. Biologic agents including TNF 
inhibitors could be prescribed by physiatrists as well as 
rheumatologists in accordance with national guidelines. 
Turkish League Against Rheumatism (TLAR) was founded 
in 1947 by Turkish physiatrists and acts as the official 
representative of Turkey in EULAR since 1947. In 2010 and 
2011, TLAR initiated a series of activities including targeted 
lectures in National Congresses and Symposiums of 
Rheumatic Diseases, reviews to be published in national 
medical journals to increase the current awareness on these 
recommendations. Recently, a project to adopt and built up 
national recommendations for the management of AS and 
RA was initiated by TLAR in order to better disseminate and 
share the knowledge of these recommendations  [6, 12]. In 
many countries, rheumatologists are the specialists who are 
primarily responsible for the management of RA. Physical 
Medicine and rehabilitation specialists (physiatrists) have 
been primarily responsible for treating rheumatic diseases 
for a very long time in Turkey. This responsibility comes 
from the regulatory laws (May 8th, 1929, No.1219 on the 
Practice of the Art of Medicine and its Branches) which 
shaped the legal framework of modern medicine in Turkey. 
Rheumatology divisions were then founded within the 
departments of PMR and Internal Medicine with the 
approval of both Ministry of Health and Council of Higher 
Education and sub-specialty programs continues since 1986 
[12]. Now the number of rheumatologist originated from 
PMR or internal medicine is nearly 200 which is still nearly 
10% of the total number of physiatrists. 
  The objective of this study was to evaluate conceptual 
agreement and rate of application of recommendations for 
the management of AS and RA in daily clinical practice 
among Turkish physiatrists. 
METHODS 
  This project was initiated by a group of Turkish 
physiatrists in collaboration with Turkish League Against 
Rheumatism (TLAR). A questionnaire was developed by the 
group consisting number of years in clinical practice, 
affiliations, mean number of patients with AS or RA seen in 
a week, and barriers or difficulties for the use of biologic 
agents. The updated 11-item ASAS/EULAR 
recommendations for the management of AS [9] and 15-item 
EULAR recommendations for the management of RA with 
synthetic and biological disease-modifying anti-rheumatic 
drugs  [9] have been translated into Turkish. The group 
collectively validated the accuracy and fluency of the 
translated text item by item. An 11-point Liekert scale was 
used to assess conceptual agreement; 0, indicated absolute 
disagreement, and 10, indicated absolute agreement. The 
survey was tagged into three pages; first, general information 
related to the self experience, affiliations, number of 
patients, barriers or difficulties for the use of biologic agents; 
second, conceptual agreement on EULAR recommendations 
for the management of RA; third, conceptual agreement on 
ASAS/EULAR recommendations for the management of 
AS. 
  The last two questions in the second and third 
“agreement” pages were “Regarding the recommendations of 
ASAS/EULAR for the management of AS, could you please 
give ratio of the overall application of these 
recommendations in your daily clinical practice while 
treating patients with AS?” and “Regarding overall 
recommendations of EULAR for the management of RA 
with synthetic and biological disease-modifying anti-
rheumatic drugs, could you please give ratio of the overall 
application of these recommendations in your daily clinical 
practice while treating patients with RA?”. These questions 
were self rated by the participant changing from 0 to 100%. 
  The questionnaire was built up and surveyed through a 
commercial website which send and collect answers on-line 
and analyze as well. Electronic mail addresses were obtained Agreement on Recommendations for AS and RA  The Open Rheumatology Journal, 2012, Volume 6   3 
from two official e-mail platforms of the societies. Mail lists 
contained only specialists in the field of physical medicine 
and rehabilitation and fellows in training were excluded. 
Links for the survey page were submitted through internet 
and all were case sensitive. All participants were allowed for 
one month to complete the survey and reminders were sent 
regularly every week. Also an invitation letter to participate 
in this survey and weekly announcements were submitted 
through the official e-mail platforms (E mail lists of Turkish 
League Against Rheumatism and Turkish Society of 
Physical Medicine and Rehabilitation). 
  Results were obtained from the website as excel sheets 
and transferred into Statistical Package for Social Sciences 
(SPSS) software. Results for the agreement were calculated 
as mean and standard deviations and demographic variables 
as cross-tabulation where appropriate. Pearson correlation 
analysis was used to assess relationship between number of 
patients and level of agreement. A p value less than 0.05 was 
accepted as statistically significant. 
RESULTS 
  The survey link was sent to 1756 e-mail addresses and 
allowed for 30 days to fill. Every week a reminder was sent 
by the system if the participants has not accepted or 
completed the online forms. Accordingly an e mail invitation 
was sent to the official e-mail lists asking for participation in 
the survey and requesting to screen junk e-mail folders for 
possible drop outs. 
  At the end of one month, 309 physiatrists (17.5%) 
completed the survey. All 309 were physiatrists and 16 had 
also sub-specialty in rheumatology (certified rheumatologist) 
and 7 had PhD degree. 
Conceptual Agreement of EULAR Recommendations for 
the Management of Rheumatoid Arthritis 
  The general characteristics of the participants completed 
questionnaire for RA are given in Table 1. Conceptual 
agreements on the items of the recommendations for the 
management of RA are given in Table 2. In Turkey, a great 
majority of the specialists who primarily care for the patients 
with AS and RA are physiatrists. In order to prevent biased 
ratings we separated only the first sentence of the 
overarching principles in which “rheumatologists” are 
underlined as the physicians who “should primarily care for 
patients with RA”. Indeed the agreement on this sole 
sentence was very poor (2.86±3.17). Nearly all of the items 
passed with an agreement score more than 7.0 except item-5. 
In this item Turkish physiatrist less agree that “in DMARD 
naïve patients, irrespective of the addition of GCs, synthetic 
DMARD monotherapy rather than combination therapy of 
synthetic DMARDs may be applied”. The self-reported 
application of overall recommendations in daily clinical 
practice was nearly 72%, which was quite satisfactory. 
Agreement of EULAR Recommendations for the 
Management of Ankylosing Spondylitis 
  The general characteristics of the participants completed 
questionnaire for AS are given in Table 3. Agreements on 
the items of the recommendations for the management of AS 
are given in Table 4. Irrespective of RA recommendations,  
 
ASAS/EULAR prefer to use “coordinated by the 
rheumatologist” which is welcomed by other physicians 
dealing with AS so we left this item as is in the survey. 
Table 1.  General Characteristic of the Physiatrist Completed 
the Pages Related to RA (n=295) 
 
Characteristics  Mean (SD) or Ratio 
Years in practice, mean (SD)  10.92(7.68) 
Number of patients with RA in a week, mean (SD)  7.72(8.73) 
Tertiary centers  
(University hospitals), %   35.3 
Tertiary centers  
(Research and training hospitals), %   15.9 
Tertiary centers  
(Rehabilitation research and training centers), %   2.7 
Secondary centers  
(State hospitals, rehabilitation centers), %  19 
Secondary centers  
(Military hospitals), %   2.4 
Secondary Centers  
(Affiliated out-patient clinics), %  0.7 
Private hospitals, %   14.2 
Private physiotherapy and rehabilitation centers, %   7.5 
Private practice or retired   2.3 
 
Table  2.  Conceptual Agreement and Self Reported Overall 
Application of EULAR Recommendations for the 
Management of RA 
 
Item Mean  SD 
Overarching principles   7.23  3.04 
Item-1 (starting DMARDs early)  8.62  2.60 
Item-2 (remission-monitoring)  9.49  1.44 
Item-3 (Methotrexate)  9.05  2.05 
Item-4 (DMARDs other than MTX)  7.99  2.21 
Item-5 (Monotherapy rather than combination)  6.28  3.09 
Item-6 (Adding GCs)  8.86  2.10 
Item-7 (Biologics when poor prognosis)  8.55  2.02 
Item-8 (responding insufficiently, start TNF inhibitors)  8.67  1.98 
Item-9 (Failure in first TNF inhibitor,  
start another TNF inhibitor or other biologics)  8.22 2.25 
Item-10 (Refractory severe RA or biologics  
contraindicated other synthetic DMARDs )  7.87 2.24 
Item-11 (Intensive medication strategies)  8.80  1.87 
Item-12 (Persistent remission tapering of biologics)  8.15  2.29 
Item-13 (Sustained long-term remission, cautious  
titration of synthetic DMARD)  8.73 1.86 
Item-14 (Poor prognostic factors combination  
of MTX with a biologic)  7.68 2.76 
Item-15 (progression of structural damage,  
comorbidities and safety concerns)  9.41 1.42 
Self-declared application of overall recommendations, %  72.42  20.53 4   The Open Rheumatology Journal, 2012, Volume 6  Ozgocmen et al. 
Table 3.  General Characteristic of the Physiatrist Completed 
the Pages Related to AS (n=275) 
 
Characteristics  Mean (SD)  
or Ratio 
Years in practice, mean (SD)  11.13(7.78) 
Number of patients with AS in a week, mean (SD)  5.80(6.65) 
Tertiary centers (University hospitals), %   36.7 
Tertiary centers (Research and training hospitals), %   15.6 
Tertiary centers  
(Rehabilitation research and training centers), %  
2.9 
Secondary centers  
(State hospitals, rehabilitation centers), % 
18.9 
Secondary centers (Military hospitals), %   2.45 
Secondary Centers (Affiliated out-patient clinics), %  0.7 
Private hospitals, %   13.5 
Private Physiotherapy and rehabilitation centers, %   6.9 
Private practice or retired   2.2 
 
Table  4.  Conceptual Agreement and Self Reported Overall 
Application of ASAS/EULAR Recommendations for 
the Management of AS 
 
Item Mean  SD 
Overarching principles   8.24  2.61 
Item-1 (General treatment)  9.50  1.30 
Item-2 (Disease monitoring)  9.26  1.42 
Item-3 (Non-pharmacological treatment)  9.60  1.19 
Item-4  
(Extra-articular manifestations and co-morbidities) 
9.52 1.26 
Item-5 (Non-steroidal anti-inflammatory drugs)  9.52  1.24 
Item-6 (Analgesics)  7.89  2.80 
Item-7 (Glucocorticoids)  8.97  1.90 
Item-8 (Disease-modifying anti-rheumatic drugs)  7.85  2.76 
Item-9 (Anti TNF therapy)  8.59  2.13 
Item-10 (Surgey )  8.38  2.19 
Item-11  
(Changes in the disease course) 
9.50 1.19 
Self-declared application of 
 overall recommendations, % 
75.71 21.20 
 
  Nearly all of the items passed with an agreement score 
more than 7.0. Relatively lesser agreement was obtained in 
analgesics and DMARD use in AS. The self-reported 
application of these recommendations in daily clinical 
practice was nearly 76% which is quite satisfactory. 
Barriers and Difficulties in the Management 
  Biologic agents in the management of RA and AS are 
available in Turkey and reimbursement strategies are 
regulated by national bylaws. Physiatrists have the right to 
prescribe these medications for the treatment of AS and RA 
as well. We asked to tick at least one (up to three most 
important) of the predefined barriers or difficulties which 
physiatrists most frequently confronted. These barriers or 
difficulties are itemed by the group and the most frequently 
ticked items in the use of biologics for the management of 
RA or AS are shown in the Table 5. 
Table  5.  Most Frequently Declared Barriers or Difficulties 
Confronted During the Management of RA or AS 
Using Biologic Agents 
 
Barriers or Difficulties  n  % 
No difficulty or barrier  43  14 
Necessity for approval of other physicians   112  36 
Long time for reporting/prescribing formalities 102 33 
Difficulties to follow up serious side effects  69  22 
Difficulties in the drug administration   50  16 
Higher costs and load to the insurance system  36  12 
Patients unwillingness to undersign predefined  
statements and consents 
25 8 
Personal or institutional discouraging experiences  
in the past 
4 1 
Other causes  70  23 
 
  The rate of application in the routine clinical practice was 
correlated with the weekly number of patients seen (for AS 
recommendations r=0.23 and for RA recommendations r=0.20, 
p<0.0001). 
DISCUSSION 
  The results from the survey revealed that conceptual 
agreement with both recommendations was very high (Level of 
agreement; mean 8.35±0.82 and 8.90± 0.67 for RA and AS 
recommendations, respectively), and the self-declared applicat-
ion of overall recommendations in the clinical practice was also 
high for both RA and AS (72.42% and 75.71%, respectively). 
Additionally, to the best of our knowledge, this survey is 
probably the first to evaluate agreement or application among 
physicians (great majority of physiatrists) other than 
rheumatologists dealing with rheumatic diseases. 
  In recommendations for the management of RA, Turkish 
physiatrists are in good agreement with the majority of the 
recommendations except the item-5. In this item the approach to 
the management of a DMARD naïve patient, irrespectively with 
additional GCs, may be the monotherapy with synthetic DMA 
RD rather than combination therapy of synthetic DMARDs. 
Although the authors of the EULAR recommendations stated 
that there is not robust evidence for the general superiority of 
DMARD combinations in comparison with respective 
monotherapies, additional GC may cause some compelling 
results [11]. This may be the effect of slightly reduced rating of 
this item by the physiatrists. Agreement on the recommen-
dations for the management of AS was slightly higher. Nearly 
all of the items of ASAS/EULAR recommendations are 
welcomed by the Turkish physiatrists. The third item related to 
the non-pharmacological management of AS had the highest 
agreement score (9.60). This agreement is especially important Agreement on Recommendations for AS and RA  The Open Rheumatology Journal, 2012, Volume 6   5 
for the fact that Turkish physiatrists actively involved in the 
physiotherapy and rehabilitation process of the patients with AS 
and have vast experience in this field. Unlike some of the 
western countries, costs of the physiotherapy and rehabilitation 
are completely reimbursed by the insurance system if prescribed 
and conducted by the physiatrists. Regarding the whole score of 
agreement, our results are in accordance with the previous 
survey evaluating these recommendations among rheumato-
logists from different countries not including Turkey [2]. The 
mean±SD score obtained in that study was 8.90±0.9 which is 
quite similar to ours (8.90±0.67), revealing that Turkish 
physiatrists share same thoughts with rheumatologists from 
different countries. 
  In our survey we prefer to use the self-rating of the overall 
recommendations in daily practice rather than rating all the 
items individually. Some of the drugs stated in the items are not 
reimbursed if not applied in the tertiary centers (i.e. some of the 
biologics) so the physicians from secondary centers would fail 
to score applicability of these items. Therefore we thought that 
rating the whole items together would be much more feasible. 
Indeed the overall rate of self-reported application was plausibly 
good for both recommendations (>70%). 
  In this survey barriers or difficulties in the treatment of RA 
or AS using biologic agents were assessed. Only 14% of 
participants noted no difficulty and the rest of participants ticked 
at least one of the pre-defined barriers or difficulties. Prescribing 
and application rules for the use of biologic agents in the 
treatment of rheumatic diseases are defined by the drug 
commissions of Ministry of Health and the costs are reimbursed 
by the national social security system in terms of bylaws. It is 
necessary to document the screening of tuberculosis and 
malignancies with joint report undersigned by the referring 
physician (a physiatrist or a rheumatologist), an internist and a 
chest physician. The participants underlined the most frequently 
confronted barriers or difficulties as the necessity for approval 
of other physicians, long time for reporting/prescribing 
formalities and safety concerns. Previous survey on 
ASAS/EULAR recommendations for AS also underscores 
similar barriers, such as national limitations to prescribe these 
expensive drugs or a general lack of adequate resources and/or 
poor infrastructure  [2]. 
  This survey study has some limitations, like relatively low 
response rate. The allowed time period (one month) for filling 
the survey might not be long enough and the survey pages may 
be relatively long that contains too much items for both RA and 
AS recommendations. Some of the participants might have been 
inevitably bored filling this long survey. We think that some of 
the non-responders, particularly those in specific rehabilitation 
centers who are not frequently treating patients with RA and 
AS, did not fill the survey. There may be also other technical 
factors like undesired filtering of the survey link mails by the 
junk mail filters or etc which further increased the drop outs. 
These technical factors will be probably overcome by the new 
software or other technological innovations. 
  As a consequence, Turkish physiatrists are in good 
conceptual agreement with the evidence-based recommendat-
ions for the management of AS and RA. These efforts may 
serve disseminating the knowledge and increasing the current 
awareness among physicians who serve these patients. Also the 
implementation of these recommendations in daily clinical 
practice will increase with such efforts. 
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